Core Insights - Entero Therapeutics, Inc. has secured a $2 million revolving loan agreement to strengthen its balance sheet and support operations while preparing for a public offering [1][3] - The company appointed three new members to its Board of Directors as a condition of the loan, replacing three existing members [2] Company Developments - The new Board members include Richard Paolone, Eric Corbett, and Manpreet Uppal, who bring diverse expertise in securities law, capital markets, and corporate finance [2] - The resignations of James Sapirstein, Alastair Riddell, and Timothy Ramdeen from the Board were noted, with the company expressing gratitude for their contributions [2][3] Business Focus - Entero Therapeutics specializes in developing targeted, non-systemic therapies for gastrointestinal diseases, addressing significant unmet needs in GI health [4] - Key programs include latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for patients with exocrine pancreatic insufficiency [4]
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members